ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Effective"

  • Abstract Number: 426 • 2013 ACR/ARHP Annual Meeting

    Characteristics of Protocol-Specified Responders/Non-Responders Treated With Etanercept Plus Methotrexate in Period 1 of the Prize Study

    Paul Emery1, Annette Szumski2, Jack Bukowski3, Eustratios Bananis2 and Lisa Marshall4, 1Institute Rheumatic and Musculoskeletal Medicine University of Leeds, Leeds, United Kingdom, 2Specialty Care, Pfizer Inc., Collegeville, PA, 3Department of Specialty Care, Pfizer Inc, Collegeville, PA, 4Pfizer Inc., Collegeville, PA

    Background/Purpose: Although frequently effective, treatment with synthetic or biologic disease-modifying antirheumatic drugs (DMARDs) does not adequately control disease activity in all patients. Prompt identification of…
  • Abstract Number: 355 • 2013 ACR/ARHP Annual Meeting

    Response To Etanercept With Or Without Methotrexate Combination Therapy In Patients With Psoriatic Arthritis

    Bernard Combe1, Urs Kerkmann2, Fiona Brock3 and Gaia Gallo2, 1Hôpital Lapeyronie-Service d'Immuno-rhumatologie, Montpellier, France, 2Pfizer Europe, Rome, Italy, 3Quanticate, Hitchin, Hertfordshire, United Kingdom

    Background/Purpose:  Randomized controlled trials in psoriatic arthrtitis (PsA) have allowed treatment with TNF inhibitors (TNFi) as monotherapy as well as co-medication with methotrexate (MTX), but…
  • Abstract Number: 281 • 2013 ACR/ARHP Annual Meeting

    GO-Kids Imaging Substudy: MRI Treatment Response To 30 Mg/m2 4-Weekly Subcutaneous  injections Of Golimumab In Children With Polyarticular JIA – Preliminary Results Of The Open Label Portion

    Nikolay Tzaribachev1, Catrin Tzaribachev1 and Bernd Koos2, 1Pediatric Rheumatology, PRI - Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, 2Clinic of Orthodontics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany

    GO-KIDS Imaging Substudy: MRI treatment response to 30 mg/m2 4-weekly subcutaneous injections of Golimumab in children with polyarticular JIA– preliminary results of the open label…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology